Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and T-cell engagers.

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable ...

FAYETTEVILLE, GA, UNITED STATES, March 10, 2026 /EINPresswire.com/ -- Chronic diabetic wounds fail to heal because ...

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatm ...

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update ...

The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).

Ivonescimab targets patients with EGFR-mutated NSCLC who progressed after EGFR TKI treatment, showing significant PFS and response rate improvements in the HARMONi trial. The dual inhibition of PD-1 ...

Aims The purpose of this study is to investigate whether gene polymorphisms of the vascular endothelial growth factor A (VEGF-A) and its receptor (VEGFR-2) have a pharmacogenetics effect on the ...

Sustained-release intraocular implants represent a rapidly advancing class of ophthalmic drug-delivery platforms engineered to maintain therapeutic intraocular concentrations over months to years. By ...